Atara transferred the BLA to Pierre Fabre, which already handles manufacturing, regulatory, and commercial activities for Ebvallo in Europe.

The firm will use proceeds to complete clinical proof of concept of its lead gene therapy programs in rare, inherited retinal diseases.

Researchers presented new data on Phenomix Sciences' genetic risk scores at the Obesity Society's ObesityWeek conference.

Sales of the leukemia drug Blincyto grew 20 percent to $392 million, but Lumakras sales decreased 2 percent to $96 million, compared to Q3 2024.

The agency is establishing a network of care centers to expand access to regenerative medicine beyond regions served by major ...

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

The firm had decreased Q3 sales for precision oncology drugs including Ibrance, Tukysa, and Bosulif, but sales increased for ...

The company will focus on advancing a program in hematological malignancies and plans to launch a registrational trial in 2026.

The firm is now offering combined ex vivo drug sensitivity and genomic testing to cancer patients outside the clinical trial setting.

The firm is refocusing its resources on a KAT6A degrader for estrogen receptor-positive breast cancer and a previously undisclosed JAK2 Inhibitor.

The firm's stock tumbled on the news, dropping from $24.45 per share at market close Monday to $15.24 per share when the market opened Tuesday.

Based on strong preclinical data on HMPL-A251 in HER2-positive tumor cell lines, the firm wants to take the therapy into clinical trials by year end.